Nanobiotix ( (NBTX) ) has issued an announcement.
On April 14, 2025, Nanobiotix disclosed transactions by persons with managerial responsibilities in line with EU Market Abuse Regulation. These transactions, which occurred between April 9 and April 14, 2025, involved acquisitions and sales of company shares on Euronext Paris, reflecting active engagement in the company’s stock by its leadership.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Underperform.
Nanobiotix’s overall stock score reflects significant financial difficulties, including negative revenue and high leverage. Technical indicators suggest weak momentum, and the stock appears overvalued relative to its earnings. The strategic partnership with JNJ offers potential future benefits but does not offset the current financial challenges. Investors should approach with caution due to the high risk associated with the company’s financial instability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a biotechnology company based in Paris, France, focusing on the development of nanomedicine products for cancer treatment. The company specializes in creating innovative solutions that enhance the efficacy of radiotherapy in oncology.
YTD Price Performance: 14.90%
Average Trading Volume: 11,140
Technical Sentiment Signal: Strong Buy
Current Market Cap: $158.3M
For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.